Anti-TNF α agents in elderly patients with rheumatoid arthritis: A study of a group of 105 over sixty five years old patients;I farmaci biologici anti-TNFα nel paziente anziano affetto da artrite reumatoide: Studio di una coorte di 105 pazienti ultra-sessantacinquenni

Reumatismo

Volumn 60, Issue 1, 2008, Pages 41-49

  Filippini, Matteo ^a   Bazzani, C ^a   Zingarelli, S ^a   Ziglioli, T ^a   Nuzzo, M ^a   Vianelli, M ^a   Biasini Rebaioli, C ^a   Cattaneo, R ^a   Gorla, R ^a  

^a SPEDALI CIVILI   (Italy)

Author keywords

Anti TNF ; Elderly patient; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; JOINT FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEROLOGY; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; DRUG ANTAGONISM; MIDDLE AGED; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 57149127008     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Scott DL, Symmons DPM, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: Result after 20 years. Lancet 1987; 1: 1108-11.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 Update. Arthritis Rheum 2002; 46: 328-46.
3. Boumpas DT, Wilder RI. Corticosteroids. In: Arthritis and allied conditions: A textbook of rheumatology. Koopmann WJ, editor. 14th ed. Philadelphia: Lippincott, Williams & Wilkins: 2001; p. 829.
4. Suarez-Almazor ME, Belseck E, Shea B,Wells G, Tugwell P. Methotrexate for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 2001; 4.
5. Östör AJ. Beyond methotrexate: Biologic therapy in rheumatoid arthritis. Clin Med 2005; 5: 222-6.
6. Probert L, Plows D, Kontogeorgos G, Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995; 25: 1794.
7. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43: 250-8.
8. Hyrich KL, Symmons PM, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disase-modifyng antirheumatic drug in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 1786-94.
9. Fautrel B, Constantin A, Morel J, et al. Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis. Joint Bone Spine 2006; 73: 433-41.
10. Deighton CM, George E, Kiely PD, Ledingham J, Luqmani RA, Scott DG. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). Rheumatology 2006; 45: 649-52.
11. van Schaardenburg D, Breedveld FC. Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 1994; 23: 367-78.
12. Ministero degli affari esteri 2006. Dati ISTAT.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
14. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. National Institute for Clinical Excellence technology Appraisal Guidance No. 36, 2002.
15. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
16. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
17. Flendrie M, Creemers MCW, Van Riel PLCM. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology 2006; 1-4.
18. Giles JT, Bartlett SJ, Gelber AC, Nanda S, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis & Rheumatism 2006; 55: 333-7.
19. Pincus T, Sokka T. Partial control of core data set measures and Disease Activity Score (DAS)measures of inflammation does not prevent long-term joint damage: Evidence from longitudinal observation over 5-20 years. Clin Exp Rheumatol 2002; 20: 5 (suppl. 27).
20. Cruyssen BV, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. DAS28 best reflects the physician's clinical judgement of response to infliximab therapy in rheumatoid arthritis patients: validation of DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005; 7: 1063-71.
21. Allanore Y, Sellam J, Batteux F, Job Deslandre C, et al. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004; 22: 756-8.
22. Gardam MA, Keystone EC, Menzies R, Manners S, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Review. Lancet Infect Dis 2003; 2: 148-55.
23. Fleishmann R M, Baumgartner S W, et al. Response to etanercept in elderly patients with rheumatoid arthritis: A retrospective analysis of clinical trial results. J Rheumatol 2003; 30: 691-6.
24. Aletaha D, Ward M M. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006; 65: 227-33.
25. Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004; 63: 221-5.
26. Gorla R, Cavagnola L. Approccio multidisciplinare nel trattamento dell'AR. Da La riabilitazione nelle malattie reumatiche. Percorsi clinici, progetto e programma riabilitativo. Fidenza 2004.
27. Genevay S, Finckh A, Ciurea A, Chamot AM, et al. Tolerance and effectiveness of anti-tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2007; 57: 679-85.